Exact Sciences Reports Clinical Study Results for Oncodetect MRD Test in Breast Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Businesswire
- Clinical Study Results: Exact Sciences presented findings at the San Antonio Breast Cancer Symposium showing that the Oncodetect® test strongly predicts distant recurrence risk in early triple-negative breast cancer patients, indicating its potential role in guiding post-surgical treatment decisions.
- Data Scale: The study analyzed data from 147 patients in the NSABP B-59 substudy, representing one of the largest datasets for triple-negative breast cancer MRD analyzed to date, thereby strengthening the clinical evidence supporting the Oncodetect test.
- Collaborative Research: Conducted in partnership with the NSABP Foundation and the German Breast Group, the study highlights the significance of ctDNA detection in managing high-risk breast cancer patients, potentially optimizing subsequent treatment strategies.
- Future Plans: Exact Sciences intends to submit these findings to a peer-reviewed journal and to MolDx for Medicare coverage support, further enhancing its market penetration in cancer diagnostics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
